Meta-analysis - reduction in risk of disease recurrence
(25%) with adjuvant chemotherapy compared to
observation (
HR=0.75,
CI: 0.68-0.83).
Only 1/21 trials received
preoperative CRT
Only 2/21 received SCPRT